



HHS Public Access

Author manuscript

Semin Respir Crit Care Med. Author manuscript; available in PMC 2016 May 20.

Published in final edited form as:

Semin Respir Crit Care Med. 2015 April ; 36(2): 169–179. doi:10.1055/s-0035-1546748.

Primary Ciliary Dyskinesia

Jason Lobo, MD [Assistant Professor of Medicine], Maimoona A Zariwala, PhD [Associate Professor of Medicine and Laboratory Medicine], and Peadar G Noone, MD, FCCP, FRCPI [Professor of Medicine]

The Division of Pulmonary Diseases, University of North Carolina Chapel Hill, NC 27599

Abstract

Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder of cilia structure, function, and biogenesis leading to chronic infections of the respiratory tract, fertility problems and disorders of organ laterality. The diagnosis can be challenging, using traditional tools such as characteristic clinical features, ciliary functional and ultra-structural defects; newer screening tools such as nasal nitric oxide levels and genetic testing add to the diagnostic algorithm. There are thirty-two known PCD causing genes, and in the future, comprehensive genetic testing may screen young infants prior to developing symptoms thus improving survival. Therapies include surveillance of pulmonary function and microbiology, in addition to airway clearance, antibiotics and ideally, early referral to bronchiectasis centers. As with CF, standardized care at specialized centers using a multidisciplinary approach likely improves outcomes. In conjunction with the CF foundation, the PCD foundation, and with lead investigators and clinicians, is developing a network of PCD clinical centers to coordinate the effort in North America and Europe. As the network grows, care and knowledge will improve.

Keywords

Bronchiectasis; cilia; ciliary dyskinesia; sinusitis; otitis; dynein arms; situs inversus; *Pseudomonas aeruginosa*

Background

Primary ciliary dyskinesia (PCD) is a rare, autosomal recessive disorder of motile cilia that leads to oto-sino-pulmonary disease.¹ PCD was first described by Kartagener et al in 1936 as a syndrome based on the triad of chronic sinusitis, bronchiectasis and situs inversus. Forty years later, Afzelius expanded on this by observing that these patients had “immotile” cilia and defective ciliary ultrastructure, specifically noting a deficiency of dynein arms, decreased mucociliary clearance and a lack of ciliary motion.^{2,3} Later on, the syndrome was renamed “primary ciliary dyskinesia” when it was observed that functional ciliary impairment without ultrastructural deformities, as well as motile cilia with obvious abnormal movement patterns could result in clinical disease.^{4–6} The prevalence of PCD is difficult to determine due to (hitherto) inadequate diagnostic methods and often an under-

Conflicts of interest

Leonard J Lobo – no conflicts of interest to disclose

recognition of the syndrome; it is estimated to be ~1 in 15,000–20,000 individuals.⁷ Focused clinical and research efforts in recent years have led to an increased understanding of the phenotype, as well as the discovery of PCD-causing genetic mutations. Indeed, the use of genetic testing has greatly aided the diagnosis of PCD and further helped the understanding of PCD. Nonetheless, even with improvements in diagnostic and screening tests at specialized centers, up to 30% of patients may be missed. Secondary ciliary dyskinesia may be seen in diseases associated with acute and chronic airway inflammation and infection.

This review will focus primarily on PCD, the genetically transmitted form of the disease, with a brief review of the structure and function of normal and dysfunctional cilia, the clinical manifestations of PCD, including diagnosis, genetic mutations, therapies and a glimpse into future.

Normal cilia structure and function

Respiratory cilia are an important part of airway host defense, protecting the airways from inhaled pathogens, allergens and other inhaled noxious particles via the mucociliary escalator. In the airways, they are surrounded by a thin, watery, peri-ciliary fluid layer overlaid by a more viscous mucus layer. The efficiency of the mucociliary escalator in defense of the airway depends on the viscosity and composition of the peri-ciliary fluid and mucus layer, the integrity of the airway epithelium and the synchrony and beat frequency of the cilia. The density of cilia decreases from the upper to the lower respiratory tract with an absence of cilia in the alveoli and air sacs.⁸ Cilia are hair-like attachments found on the epithelial cell surfaces (~200 per cell) of various organs. The cilia basal body attaches to the apical cytoplasm on the cell surface and extends into the extracellular space. They are composed of α - and β -tubulin monomers organized into longitudinal microtubules. The axonemal structure consists of a circular arrangement of nine microtubule doublets surrounding a central pair of microtubules (9+2) or with an arrangement where the central pair is absent (9+0).⁹ Cilia are categorized into 9+2 motile cilia with dynein arms, 9+0 motile cilia (nodal cilia) with dynein arms and 9+0 non-motile cilia lacking dynein arms.¹⁰

“9+2” motile cilia are found on the apical surfaces of the upper and lower respiratory tract, on the ependymal cells lining the ventricles of the central nervous system, in the oviducts and in the flagellum of sperm.¹⁰ Outer dynein arms (ODAs) and inner dynein arms (IDAs) traverse along the length of the peripheral microtubules forming a doublet (Figure 1) and are organized into nine microtubule pair doublets, surrounding a central pair. This organizational structure creates this distinctive 9+2 arrangement. The central pair is linked to the surrounding pair doublet through radial spoke proteins and the surrounding pair doublets are linked to one another via nexin linked proteins (Figure 1). The microtubules slide by one another to produce ciliary motion via an ATP-containing dynein arm on the peripheral microtubule. The protein links between the microtubules limit the degree of sliding, causing them to bend. Through coordinated and synchronized bending, wave like movements occur at ~6–12 Hz, which function to propel mucus and adherent particles/bacteria on the surface of the airway – hence the term “mucociliary escalator”. The ability of numerous adjacent cilia on airway epithelial cells to beat at such a high frequency in part reflects the very low friction among the cilia, which results from negatively charged glycoproteins that coat the

ciliary shaft. Thus, given such an efficient, if complex, system of defense, it can readily be visualized that clinical disease may result from disruptions in the various components of the system. For example, Cystic Fibrosis results from abnormalities in the Cystic Fibrosis Transmembrane Regulator (CFTR), a critical airway surface epithelial protein. Similarly, mutations in genes encoding for axonemal structures of the functional components of motile cilia, or proteins involved in the biogenesis of cilia, including cytoplasmic proteins, can result in clinical disease; PCD.^{11–14}

Although dysfunctional motile cilia lead to the main clinical manifestations of PCD, abnormal nodal motile cilia can also lead to interesting phenotypic features. Nodal cilia occur during embryonic development and have a 9+0 configuration rather than the classic 9+2 configuration and are found on the epithelial cell surface of the kidneys, the bile ducts, and the endocrine pancreas and on non-epithelial cells such as chondrocytes, fibroblasts, smooth muscle cells and neurons. In contrast to the waveform sliding motion of 9+2 cilia, nodal motile 9+0 cilia beat with a vertical /rotational motion resulting in a leftward flow of extracellular fluid which is important for cell signaling during the development of normal human left-right asymmetry. Mutations in the genes that encode the outer doublets result in laterality defects (situs inversus for example) while mutations in the genes that encode the non-directional central apparatus (central complex, radial spoke), do not.¹⁵ This represents a predictable genotype – phenotype relationship (see below).

Phenotypic features

Overview

Cells lining the nasopharynx, middle ear, paranasal sinuses, the lower respiratory tract and the reproductive tract contain cilia; these cilia are abnormal in structure and function in PCD, leading to clinical expression of disease. The clinical manifestations of PCD are thus predictable, with an age-dependent, and organ system spectrum of presentation (Table 1). Symptoms of PCD can occur at birth, or within the first several months of life. Normal ciliary function is critical in the clearance of amniotic fluid from the fetal lung; over 80% of full term neonates with PCD have a syndrome of respiratory distress. Unexplained respiratory distress, radiographic abnormalities, atelectasis in particular, and hypoxia in a full term infant should raise the suspicion for PCD.^{16,17} Almost all children with PCD have a daily productive cough, a logical symptom, since cough can partially compensate for the dysfunctional mucociliary clearance. However, recurrent bacterial infections of the lower airways ultimately leads to bronchiectasis, which is seen in virtually all adults older with PCD.^{16–18} Despite aggressive medical care, PCD is generally a progressive disease and some patients develop severe disease, respiratory failure, and/or require lung transplantation.¹

Airway microbiology

Regular surveillance of the respiratory flora is important, as a variety of organisms may colonize or infect the lung, which may require targeted therapy because of resistance, or lead to specific infectious problems (e.g. non-tuberculous mycobacteria; NTM). Monitoring protocols developed for cystic fibrosis and PCD patients vary but most centers obtain airway

cultures every 3 to 6 months. The respiratory microbiology in PCD generally mirrors that of CF, however, in PCD colonization with *Pseudomonas aeruginosa* generally occurs later, and the incidence of *S pneumoniae* is much higher.¹ Children with PCD have airway colonization with *Haemophilus influenzae*, *Staphylococcus aureus* and *Streptococcus pneumoniae* and, recently, there has been an upsurge of *P. aeruginosa* in infants/preschoolers. *P. aeruginosa* (smooth and mucoid varieties) normally occurs in teenagers and young adults and is often the dominant organism in adults with PCD. NTM are seen in ~15% of adults with PCD.¹

Lung Function

Patients with PCD, as with other patients with non-CF bronchiectasis, usually develop progressive airway obstruction as the disease advances. The disease progression is usually slower than seen in CF, however, it is just as important to follow lung function serially to establish a baseline, to help guide therapy, and to determine prognosis.^{18–20}

Radiology

High resolution chest computed tomography scan (HRCT scan) is the most sensitive imaging modality to diagnosis bronchiectasis. While HRCT cannot confidently distinguish between the different etiologies for bronchiectasis (PCD, vs idiopathic, vs post infectious etc), there are disease distributions that may support specific diseases. For example, PCD may be associated with more bronchiectasis in the middle and lower lobes, as compared with CF which usually shows more disease in upper lobes.²¹ Subtle lung disease may start early in life, as HRCT scans of infants and children with PCD show sub-segmental atelectasis, peri-bronchial thickening, mucus plugging, evidence of air trapping and ground glass opacities. HRCT may show bronchiectasis even in infancy, and its frequency increases with age. The absence of bronchiectasis on a HRCT scan of an adult virtually excludes PCD from the differential.^{21,22}

Non-pulmonary manifestations

Situs abnormalities results in early diagnosis thus it is found in ~60% of newly diagnosed pediatric patients and ~50% of newly diagnosed adults. The defect is in the 9+0 nodal motile cilium during embryogenesis whose unidirectional rotational beat determines normal thoraco-abdominal orientation. Without this, thoraco-abdominal orientation develops at random, resulting in a 50% incidence in adults.¹⁵ More recently this phenotypic expression of situs abnormalities has expanded to include other clinical manifestations, including that of cardiac abnormalities; ~6% of patients with PCD have congenital heart disease.²³ Spermatozoa depend on cilia for motility thus infertility is seen in almost all males with PCD. However, a small number of men with PCD have appeared to conceive naturally. Females have abnormal cilia in their fallopian tubes with longer ovum transit time, and there appears to be an increased incidence of infertility and ectopic pregnancies.²⁴ Less clear phenotypic associations include pectus excavatum (10%), scoliosis (5–10%), retinitis pigmentosa and hydrocephalus.²⁵

Diagnostic Approaches

A precise diagnosis of PCD may be difficult, especially in non-classic clinical situations (for example, without situs abnormalities). Often, only specialized centers have the resources to make a definitive diagnosis (see below). Obviously the presence of any laterality abnormalities, or congenital heart disease, in the presence of chronic respiratory disease should prompt the notion of PCD as a potential unifying cause. A history of unexplained neonatal respiratory distress, early onset and persistent nasal-pulmonary symptoms, unexplained bronchiectasis, a family history of PCD and immotile sperm/infertility should trigger an evaluation. There is overlap with other chronic respiratory diseases particularly CF, although immunologic deficiencies, allergic broncho-pulmonary aspergillosis (ABPA), and recurrent aspiration may also be in the differential. Early referral to a specialized center is recommended for both diagnosis and management, given the complex nature of the disease, and the rapid nature with which new information is emerging in relation to diagnosis and management.

Indirect assessment of ciliary function

Saccharin Test—The saccharin test was a traditional simple, indirect way to test ciliary function, and was used as a screening tool for PCD at many centers. A 1–2mm particle of saccharin is placed on the inferior nasal turbinate and the time it takes the patient to taste the saccharin is a rough estimate of nasal mucociliary clearance. However, at best it is crude, limited by technical errors (inadequate placement of saccharin), patient compliance (unable to sit still for test, especially children) and false positives (poor sense of taste, rhinosinusitis). Thus, it is rarely used currently, and has been superseded by the more accurate tests below.

Nasal Nitric Oxide (NO) levels—The fortuitous observation several years ago that levels of NO produced in the upper airway are reduced in PCD led to the concept that nasal NO levels could be used as screening test in PCD.²⁶ NO is produced by the para-nasal sinus epithelium via NO-synthase and low levels are seen in PCD, CF, acute/chronic sinusitis and nasal polyposis. In patients with PCD however, levels of exhaled NO are extremely low (~10% of normal value) when compared to these other diseases. Interestingly, carriers of PCD have been shown to have intermediate levels of exhaled NO.^{1,27,28} Using a standardized protocol, nasal NO measurements can accurately identify patients with PCD 98.6% of the time.²⁹

Direct assessment of ciliary function

Microscopic analysis—Function can be classed as qualitatively normal, dyskinetic or immotile with direct visualization of ciliary beat pattern and frequency with microscopic analysis of trans-nasal brushings or nasal scrapes of the inferior turbinate. However, this test is technically difficult outside of research centers, and is neither sensitive nor specific.³⁰

High-speed digital video imaging—Trans-nasal brushing or nasal scrape ciliated epithelial samples can be analyzed with high-speed digital video imaging to get quantitative measurements of the ciliary beat frequency (CBF) to help differentiate between abnormally beating cilia and normal beat patterns.^{9,31} The cilium can be viewed in slow motion, with

40–50 frames per ciliary beat cycle. Normal cilia beat back and forth within the same frame with no sideways recovery sweep. CBF and beat pattern abnormalities are associated with specific ultra-structural defects including transposition and defects in isolated outer arms, isolated inner arms and radial arms.³² Active sinusitis can cause secondary ciliary dysfunction resulting in false positives, and thus samples should be obtained when the patient is relatively stable clinically. A normal CBF and beat pattern is sensitive enough to exclude classic PCD, but any abnormality should provoke further testing.²⁷ Thus, this test (like other studies of cilia, often available at only research centers) should be used along with structural, and genetic analysis to confirm the diagnosis.

Assessment of ciliary ultrastructure

Transmission electron microscopy³³—Once the suspicion for PCD is high, the axonemal structure of the respiratory cilia may be studied using transmission electron microscopy, the traditional way of diagnosing PCD since Afzelius' first report in the mid-1970s.² Various ciliary ultrastructural defects have been described, including the absence of, or alteration in, inner dynein arms (IDAs) or outer dynein arms (ODAs), absence of the central pair, or defect of radial spokes.³⁴ The most common ultra-structural defect in PCD is either the absence or shortening of an ODA (55% prevalence) or a combined absence/shortening of both the IDA and the ODA (15% prevalence). Other abnormalities include defects in the IDA alone or in combination with defects in radial spokes, central microtubule pairs (transposition) or central microtubular agenesis. Thus, until recently, the identification of ultrastructural defects on TEM was the “gold standard” for the diagnosis, however, with advances in our molecular understanding in PCD, it is known that ~30% of patients with genetically proven PCD have normal ciliary ultrastructure and in some cases, a ciliary a- or oligoplasia, hence inadequate for the TEM analysis. In addition, the technique is limited by false positive conditions (those associated with active mucosal epithelium inflammation, viral or bacterial), inadequate samples, poorly processed samples and reader error.^{35–38} Studies have shown a 3–10% prevalence of defective cilia in the airways of healthy individuals, and normal ultrastructure in up to 15% of PCD patients.³⁹ Dependence on TEM alone therefore is an unreliable way of solely diagnosing PCD.

Flourescence-labeled antibodies—Immunoflourescent analysis using antibodies directed against the main axonemal components has been used to identify structural abnormalities of cilia. For example, PCD patients with ODA defects have absence of DNAH5 staining from the entire axoneme and accumulation of DNAH5 at the microtubule organizing center. Antibody based techniques can diagnose defects in both the ODAs and the IDAs caused by the KTU mutation in PCD. Currently, a panel of antibodies directed towards multiple ciliary proteins is being developed that may add to the diagnostic armamentarium in screening for PCD, however, like many sophisticated techniques, it is restricted to a few centers that have this technology.⁴⁰

Genetic testing

PCD is a recessive disorder, and exhibits locus and allelic heterogeneity. That is, multiple genes are involved in the disease, and different mutations in the same gene may also cause PCD. Mutations in eleven different PCD- causing genes have been described between 1999

and 2010 with linkage mapping and/or candidate gene testing. An additional 23 genes have been discovered since 2011 owing to the availability of whole exome sequencing (Table 2). Some of these genes (for example DNAH8 and NME8) have only been seen in few patients, thus replication studies are necessary. About 80% of the mutations are loss-of-function variants (nonsense, frame shift, or defective splice mutations) while the others are conservative missense mutations or in-frame deletions. Most mutations occur in only one patient/family (“private” mutations) a few of the mutations have been seen to recur in two or more unrelated patients. Collaborative efforts in recent years have allowed the collection of large amounts of data from across many clinical centers in the US and Canada and thus facilitated large scale genetic studies and identification of many causative genes, which had previously been very difficult to do in this rare disease.⁴¹ Approximately 65% of the 200 PCD patients in the rare disease consortium (Genetic Disorders of Mucociliary clearance; GDMCC) have biallelic mutations (mutations in both copies of the same gene). At this point, with the use of next generation sequencing, ~66% of patients with PCD can be identified therefore facilitating early diagnosis and treatment.^{40,42–45} This is especially helpful in the cases where ciliary ultrastructural analysis is equivocal or inadequate.

As the basic structure of the cilia is highly conserved across species, non-human models have helped in the discovery of PCD genes and the effects of the mutations on the cilia. Multiple publications have documented the effects of specific mutations on the cilia structure and function. Some of the genes code for proteins in the ODA, IDA or radial spoke causing specific dysfunction or dysmotility while others are expressed by proteins in the cytoplasm used for the pre-assembly of the cilia causing loss of both the ODA and the IDA leading to cilia immotility.^{43,46–48} Recently, two proteins (CCNO and MCIDAS) have been shown to affect cilia biogenesis.^{49,50} Specific classes of mutations are associated with specific phenotypes. Mutations in genes that lead to loss of function of the cilia also lead to low nasal nitric oxide (NO) levels (<77nl/min). Mutations that affect the dynein arm’s ultrastructure lead to situs abnormalities while mutations that affect the central apparatus do not. Mutations in patients with normal TEM can have cilia with normal beat frequencies and waveforms.

Overall, the more that is learnt about the molecular basis of PCD, the more is learnt about the spectrum of phenotypes, ranging from “classic” to mild, that associated with late presentation, or that with normal cilia structure, analogous to the experience with CF – classic, early presentation disease versus non-classic disease often presenting later in life, or even well into adulthood.

Therapies

As there are currently no therapies available that can reverse the underlying ciliary abnormalities, the goals of therapy are to prevent exacerbations and slow the progression of the disease. As with other forms of CF and non-CF bronchiectasis, patient education is a critical part of the care plan, including imparting an understanding of the underlying cause of the disease, its prognosis and the various therapies available to try to control the symptoms, especially airway clearance. Currently, there are no data from randomized clinical trials to support any particular forms of therapy, thus, most management strategies

(including those discussed below) are extrapolated from CF and non-CF bronchiectasis. As with any chronic disease, usual good health practices such as refraining from smoking, and administration of recommended immunizations including influenza, and pneumococcal vaccines.

Surveillance

To guide the management plan, regular (twice yearly to quarterly) lung function testing is recommended, together with microbiologic assessments of airway flora (using either expectorated sputum, or induced samples using 3–7% hypertonic saline) is recommended to establish clinical trends and detect exacerbations, thus allowing targeted anti-microbial therapy. A baseline computed tomogram (CT) scan is useful to assess the nature and extent of disease (as noted above bronchiectasis may be evident even in young patients), followed by periodic chest imaging to track disease progress, or, to assess the significance of new pathogens such as multi drug-resistant gram negative organisms, or non-tuberculous mycobacteria.

Airway Clearance

Physiotherapy

There are no data to support any particular form of airway clearance in PCD, but clinical experience supports its use in a form acceptable to the patient. Daily airway clearance with cardiovascular exercise, use of percussion vests, manual chest physical therapy and valve/positive pressure expiratory devices help mobilize and aid expectoration of broncho-pulmonary secretions, improve efficiency of ventilation, maintain/improve exercise tolerance and reduce breathlessness.

Osmotic agents

“Hydration” therapy of the airway is an attractive concept to augment clearance of secretions in a disease such as PCD, in this case “cough clearance” given the dysfunctional cilia.⁵¹ Nebulized hypertonic saline (3%–7% hypertonic saline) modulates the liquid content of the peri-ciliary fluid layer via increased hydration, thinning thick secretions and triggering cough in the CF population. It has been shown to improve lung function, quality of life, and reduce antibiotic needs in the non-CF bronchiectasis population.^{51,52} More recently, another agent which works via the osmotic approach is inhaled mannitol, again studied in non CF bronchiectasis rather than specifically PCD.⁵³ Although the inhaled drug (400 mg BID) did not achieve its primary outcome of reducing exacerbations, it did perform better than placebo (low dose mannitol) in slowing down the time to first exacerbation and improving the quality of life measures.

Deoxyribonuclease (Dornase α)

Dornase α is an enzyme that hydrolyses eukaryotic DNA released from decaying neutrophils to reduce mucus viscosity and aid airway clearance in the CF population.⁵⁴ It is however, not beneficial in the non-CF bronchiectasis population, as studies show that the drug is associated with pulmonary exacerbations and a decline in lung function.⁵⁵

Antibiotics

Given the propensity for chronic infection, as with other forms of bronchiectasis, antibiotics are the cornerstone of treatment for PCD exacerbations (usually associated with an increase in cough, dyspnea, wheeze, with a change in sputum volume or character, or purulence, or hemoptysis) as they generally improve symptoms and hasten recovery.^{56,57} Antibiotic therapy should be based on prior respiratory culture data, and previous therapeutic responses. Susceptibility patterns and clinical responses may guide physicians between oral, inhaled and intravenous routes of administration. There are no randomized data to support any particular drug, or route of administration, and clinical judgment is required; however, milder exacerbations often respond to oral or oral/inhaled combinations, while more significant exacerbations usually require systemic antibiotics (in combination, if gram negative organisms are cultured). There is a good deal of interest in the development of inhaled antibiotics in recent years in non-CF bronchiectasis, and over the next five to ten years it is likely there will be more approved drugs with better evidence of efficacy available (a reduction in exacerbation frequency, bacterial burden) for example inhaled aminoglycosides, and quinolones.^{58–60} Early attempts to eradicate newly acquired bacteria, especially *P. aeruginosa*, are recommended however, this has not been shown to preserve lung function. Chronic or cycling oral or inhaled antibiotics may be used in patients with frequent exacerbation to try to improve quality of life, reduce exacerbations and (hopefully) stabilize lung function.^{56,58,61,62}

Anti-inflammatories

A variety of anti-inflammatory agents including oral prednisone, inhaled corticosteroids and macrolides have been used in airways disease associated with bronchiectasis. Prednisone is generally not efficacious in the CF population outside of co-existent asthma, and ABPA and there are no studies in the PCD population. Inhaled corticosteroids have not been shown to be beneficial in non-CF bronchiectasis.

The best data for “preventive” therapy comes from recent studies using oral macrolides which have shown promising outcomes in non-CF bronchiectasis, with reductions in exacerbation frequency, delayed time to first exacerbation and reduced hospitalizations. It is unclear if this benefit is from an anti-inflammatory or antimicrobial effect. Prior to initiating therapy with a macrolide, patients should be tested for NTM, in case macrolides should form part of a multi-drug regimen, and to avoid the emergence of resistance from chronic single agent macrolide use.^{63–65}

Miscellaneous approaches

Lung resection—Surgery may be considered in areas of localized lung disease if it is causing severe systemic symptoms, frequent exacerbations or recurrent/life threatening hemoptysis despite aggressive medical therapy. Patients in such situations have undergone successful resection but long-term data are lacking.⁶⁶ Often the diffuse nature of disease elsewhere in the lung mitigates against the likelihood of success in resecting more diseased parts of the lung.

Lung transplant—PCD patients undergoing double lung transplantation generally have good survival outcomes (personal communication?). The usual concerns pertain to candidacy for the procedure, but also specifically include multiply drug resistant organisms, and poor nutritional status. Interestingly, patients with *situs inversus*, do not pose any additional risk to post-transplant outcomes; the anatomic disorientation is challenging but not a contraindication.⁶⁷

Extra pulmonary disease management

Otitis media—Management may be controversial, especially in the pediatric community. The long-term sequelae of chronic disease in the upper airway include conductive hearing loss, delayed speech and language development, and cholesteatoma formation. Standard medical therapy is recommended for acute episodes. There are not enough data on surgical tympanostomy to make a definitive statement regarding its utility; experts argue against the utility of this approach.²⁷ Regular audiology assessments are encouraged.^{68,69}

Chronic Sinusitis—As with CF, the sinuses are usually involved. Management includes nasal steroids, nasal lavage and intermittent antibiotic lavages and systemic antibiotics. Otolaryngology evaluation for surgery and polypectomy to promote sinus drainage is helpful for patients refractory to medical therapy.⁷⁰

Infertility—Male infertility is secondary to sperm immotility and assisted fertilization techniques such as intra-cytoplasmic sperm injections are promising. Female infertility is secondary to sluggish fallopian tube transit time and direct ovum harvesting with in vitro fertilization leads to successful pregnancy.

Prognosis

As compared with CF, the disease severity and deterioration in lung function is less marked, especially with appropriate medical therapy. A study by Ellerman and Bisgaard reported that adults had worse lung function at time of diagnosis as compared to adolescents, however, once diagnosed and therapy started, no further lung deterioration was noted.⁷¹ However, other studies have shown progression to severe lung disease prior to adult hood. These discrepancies in severity and survival may relate at least in part to the genetic and phenotypic heterogeneity of PCD, as well as the usual aspects of access to care, socio-economic backgrounds, of patients, and accompanying co-morbidities. Overall, the majority of patients with PCD appear to have a near normal life expectancy when compliant with recommended therapies. A minority of patients develop progressive severe bronchiectasis, end stage lung disease and early death, unless they undergo lung transplantation.⁷¹

Summary and into the future

In the past two decades, much has been learned about PCD. Accurate and earlier diagnosis is possible, and access to specialized centers has become easier. Standardized care at specialized centers using a multidisciplinary approach is expected to improve outcomes. The recent creation of the PCD foundation has facilitated the creation of a network of PCD clinical centers to help achieve this goal. As the network grows, and clinicians and research

scientists accumulate more data from growing numbers of PCD patients, care and knowledge will undoubtedly improve. In parallel, genetics correlates with larger clinical datasets have shown that PCD is a genetically heterogeneous disease with different mutations in several genes resulting in a phenotype spectrum, across many races and ethnic groups. The severity of disease ranges from mild to severe. Delays in recognition may result in the development and progression of irreversible lung disease. In CF, early identification and diagnosis leads to early treatment and frequent monitoring to decrease morbidity and mortality, and one assumes the same principles apply to PCD, despite differences in pathogenesis. Still, it must be remembered that PCD is not the same as CF, and management is not identical. Without large numbers of patients with PCD, there has hitherto been little incentive for industry to pursue drug development, thus currently we rely on studies in non-CF bronchiectasis (muco-active agents, macrolides, inhaled antibiotics). However, as noted above, with the creation of clinical and research networks, with improved identification and more accurate diagnosis of PCD, we can expect larger cohorts of PCD patients available to participate in longitudinal studies of the natural history of the disease, as well as studies of novel therapies, with the goal of improving clinical care and outcomes in this rare disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors acknowledge the support of many patients, colleagues, the PCD Foundation and the Genetics Consortium, that have supported the clinical investigation into the PCD related work reported in this review and elsewhere.

Maimoona Zariwala- supported by National Institutes of Health grants R01 HL071798 and 5U54HL096458. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Peadar Noone – Early work in PCD was supported by NIH HL04225. Has participated in clinical studies of the safety and efficacy inhaled mannitol (supported by Pharmaxis), inhaled aztreonam (supported by Gilead) and inhaled liposomal ciprofloxacin (supported by Aradigm) in patients with non-CF bronchiectasis.

Has sat on an advisory committee for Bayer to develop novel therapies for non-CF bronchiectasis.

References

1. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. *American journal of respiratory and critical care medicine*. 2004; 169:459–67. [PubMed: 14656747]
2. Afzelius BA. A human syndrome caused by immotile cilia. *Science*. 1976; 193:317–9. [PubMed: 1084576]
3. Eliasson R, Mossberg B, Camner P, Afzelius BA. The immotile-cilia syndrome. A congenital ciliary abnormality as an etiologic factor in chronic airway infections and male sterility. *The New England journal of medicine*. 1977; 297:1–6. [PubMed: 301245]
4. Sturgess JM, Chao J, Wong J, Aspin N, Turner JA. Cilia with defective radial spokes: a cause of human respiratory disease. *The New England journal of medicine*. 1979; 300:53–6. [PubMed: 152870]
5. Wakefield S, Waite D. Abnormal cilia in Polynesians with bronchiectasis. *The American review of respiratory disease*. 1980; 121:1003–10. [PubMed: 6968169]

6. Herzon FS, Murphy S. Normal ciliary ultrastructure in children with Kartagener's syndrome. *The Annals of otology, rhinology, and laryngology*. 1980; 89:81–3.
7. Leigh MW, O'Callaghan C, Knowles MR. The challenges of diagnosing primary ciliary dyskinesia. *Proceedings of the American Thoracic Society*. 2011; 8:434–7. [PubMed: 21926395]
8. Toskala E, Smiley-Jewell SM, Wong VJ, King D, Plopper CG. Temporal and spatial distribution of ciliogenesis in the tracheobronchial airways of mice. *American journal of physiology Lung cellular and molecular physiology*. 2005; 289:L454–9. [PubMed: 15879461]
9. Chilvers MA, Rutman A, O'Callaghan C. Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults. *Thorax*. 2003; 58:333–8. [PubMed: 12668798]
10. Satir P, Christensen ST. Overview of structure and function of mammalian cilia. *Annual review of physiology*. 2007; 69:377–400.
11. Zariwala MA, Knowles MR, Omran H. Genetic defects in ciliary structure and function. *Annual review of physiology*. 2007; 69:423–50.
12. Mitchell B, Stubbs JL, Huisman F, Taborek P, Yu C, Kintner C. The PCP pathway instructs the planar orientation of ciliated cells in the *Xenopus* larval skin. *Current biology: CB*. 2009; 19:924–9. [PubMed: 19427216]
13. Mitchell B, Jacobs R, Li J, Chien S, Kintner C. A positive feedback mechanism governs the polarity and motion of motile cilia. *Nature*. 2007; 447:97–101. [PubMed: 17450123]
14. Sears PR, Thompson K, Knowles MR, Davis CW. Human airway ciliary dynamics. *American journal of physiology Lung cellular and molecular physiology*. 2013; 304:L170–83. [PubMed: 23144323]
15. Basu B, Brueckner M. Cilia multifunctional organelles at the center of vertebrate left-right asymmetry. *Current topics in developmental biology*. 2008; 85:151–74. [PubMed: 19147005]
16. Sagel SD, Davis SD, Campisi P, Dell SD. Update of respiratory tract disease in children with primary ciliary dyskinesia. *Proceedings of the American Thoracic Society*. 2011; 8:438–43. [PubMed: 21926396]
17. Ferkol T, Leigh M. Primary ciliary dyskinesia and newborn respiratory distress. *Seminars in perinatology*. 2006; 30:335–40. [PubMed: 17142159]
18. Brown DE, Pittman JE, Leigh MW, Fordham L, Davis SD. Early lung disease in young children with primary ciliary dyskinesia. *Pediatric pulmonology*. 2008; 43:514–6. [PubMed: 18383332]
19. Santamaria F, Montella S, Tiddens HA, et al. Structural and functional lung disease in primary ciliary dyskinesia. *Chest*. 2008; 134:351–7. [PubMed: 18403663]
20. Green K, Buchvald FF, Marthin JK, Hanel B, Gustafsson PM, Nielsen KG. Ventilation inhomogeneity in children with primary ciliary dyskinesia. *Thorax*. 2012; 67:49–53. [PubMed: 21953064]
21. Kennedy MP, Noone PG, Leigh MW, et al. High-resolution CT of patients with primary ciliary dyskinesia. *AJR American journal of roentgenology*. 2007; 188:1232–8. [PubMed: 17449765]
22. Jain K, Padley SP, Goldstraw EJ, et al. Primary ciliary dyskinesia in the paediatric population: range and severity of radiological findings in a cohort of patients receiving tertiary care. *Clinical radiology*. 2007; 62:986–93. [PubMed: 17765464]
23. Kennedy MP, Omran H, Leigh MW, et al. Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia. *Circulation*. 2007; 115:2814–21. [PubMed: 17515466]
24. Munro NC, Currie DC, Lindsay KS, et al. Fertility in men with primary ciliary dyskinesia presenting with respiratory infection. *Thorax*. 1994; 49:684–7. [PubMed: 8066563]
25. Engesaeth VG, Warner JO, Bush A. New associations of primary ciliary dyskinesia syndrome. *Pediatric pulmonology*. 1993; 16:9–12. [PubMed: 8414746]
26. Lundberg JO, Weitzberg E, Nordvall SL, Kuylenstierna R, Lundberg JM, Alving K. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. *The European respiratory journal*. 1994; 7:1501–4. [PubMed: 7957837]
27. Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. *The European respiratory journal*. 2009; 34:1264–76. [PubMed: 19948909]

28. Walker WT, Jackson CL, Lackie PM, Hogg C, Lucas JS. Nitric oxide in primary ciliary dyskinesia. *The European respiratory journal*. 2012; 40:1024–32. [PubMed: 22408195]
29. Leigh MW, Hazucha MJ, Chawla KK, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. *Annals of the American Thoracic Society*. 2013; 10:574–81. [PubMed: 24024753]
30. Santamaria F, de Santi MM, Grillo G, Sarnelli P, Caterino M, Greco L. Ciliary motility at light microscopy: a screening technique for ciliary defects. *Acta paediatrica*. 1999; 88:853–7. [PubMed: 10503685]
31. Olm MA, Kogler JE Jr, Macchione M, Shoemark A, Saldiva PH, Rodrigues JC. Primary ciliary dyskinesia: evaluation using cilia beat frequency assessment via spectral analysis of digital microscopy images. *Journal of applied physiology*. 2011; 111:295–302. [PubMed: 21551013]
32. Stannard WA, Chilvers MA, Rutman AR, Williams CD, O’Callaghan C. Diagnostic testing of patients suspected of primary ciliary dyskinesia. *American journal of respiratory and critical care medicine*. 2010; 181:307–14. [PubMed: 19910612]
33. Altemeier WA, Liles WC, Villagra-Garcia A, Matute-Bello G, Glenn RW. Ischemia-reperfusion lung injury is attenuated in MyD88-deficient mice. *PloS one*. 2013; 8:e77123. [PubMed: 24146959]
34. Shoemark A, Dixon M, Corrin B, Dewar A. Twenty-year review of quantitative transmission electron microscopy for the diagnosis of primary ciliary dyskinesia. *Journal of clinical pathology*. 2012; 65:267–71. [PubMed: 22135026]
35. Chilvers MA, Rutman A, O’Callaghan C. Ciliary beat pattern is associated with specific ultrastructural defects in primary ciliary dyskinesia. *The Journal of allergy and clinical immunology*. 2003; 112:518–24. [PubMed: 13679810]
36. O’Callaghan C, Rutman A, Williams GM, Hirst RA. Inner dynein arm defects causing primary ciliary dyskinesia: repeat testing required. *The European respiratory journal*. 2011; 38:603–7. [PubMed: 21406509]
37. Jorissen M, Willems T. The secondary nature of ciliary (dis)orientation in secondary and primary ciliary dyskinesia. *Acta oto-laryngologica*. 2004; 124:527–31. [PubMed: 15224888]
38. Olin JT, Burns K, Carson JL, et al. Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: A multicenter experience. *Pediatric pulmonology*. 2011
39. Morillas HN, Zariwala M, Knowles MR. Genetic causes of bronchiectasis: primary ciliary dyskinesia. *Respiration; international review of thoracic diseases*. 2007; 74:252–63.
40. Panizzi JR, Becker-Heck A, Castleman VH, et al. CCDC103 mutations cause primary ciliary dyskinesia by disrupting assembly of ciliary dynein arms. *Nature genetics*. 2012; 44:714–9. [PubMed: 22581229]
41. Genetic Disorders of Mucociliary Clearance Consortium(GDMCC). <http://rarediseasesnetwork.epi.usf.edu/gdmcc/index.htm>. at <http://rarediseasesnetwork.epi.usf.edu/gdmcc/index.htm>
42. Merveille AC, Davis EE, Becker-Heck A, et al. CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs. *Nature genetics*. 2011; 43:72–8. [PubMed: 21131972]
43. Antony D, Becker-Heck A, Zariwala MA, et al. Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms. *Human mutation*. 2013; 34:462–72. [PubMed: 23255504]
44. Olbrich H, Schmidts M, Werner C, et al. Recessive HYDIN mutations cause primary ciliary dyskinesia without randomization of left-right body asymmetry. *American journal of human genetics*. 2012; 91:672–84. [PubMed: 23022101]
45. Olbrich H, Horvath J, Fekete A, et al. Axonemal localization of the dynein component DNAH5 is not altered in secondary ciliary dyskinesia. *Pediatric research*. 2006; 59:418–22. [PubMed: 16492982]
46. Horani A, Druley TE, Zariwala MA, et al. Whole-exome capture and sequencing identifies HEATR2 mutation as a cause of primary ciliary dyskinesia. *American journal of human genetics*. 2012; 91:685–93. [PubMed: 23040496]

47. Kott E, Duquesnoy P, Copin B, et al. Loss-of-function mutations in LRRC6, a gene essential for proper axonemal assembly of inner and outer dynein arms, cause primary ciliary dyskinesia. *American journal of human genetics*. 2012; 91:958–64. [PubMed: 23122589]
48. Mazor M, Alkrinawi S, Chalifa-Caspi V, et al. Primary ciliary dyskinesia caused by homozygous mutation in DNAL1, encoding dynein light chain 1. *American journal of human genetics*. 2011; 88:599–607. [PubMed: 21496787]
49. Boon M, Wallmeier J, Ma L, et al. MCIDAS mutations result in a mucociliary clearance disorder with reduced generation of multiple motile cilia. *Nature communications*. 2014; 5:4418.
50. Watson CM, Crinnion LA, Morgan JE, et al. Robust diagnostic genetic testing using solution capture enrichment and a novel variant-filtering interface. *Human mutation*. 2014; 35:434–41. [PubMed: 24307375]
51. Noone PG, Bennett WD, Regnis JA, et al. Effect of aerosolized uridine-5'-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. *American journal of respiratory and critical care medicine*. 1999; 160:144–9. [PubMed: 10390392]
52. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. *Respiratory medicine*. 2011; 105:1831–5. [PubMed: 22018993]
53. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. *Thorax*. 2014
54. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. *The New England journal of medicine*. 1994; 331:637–42. [PubMed: 7503821]
55. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. *Chest*. 1998; 113:1329–34. [PubMed: 9596315]
56. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. *American journal of respiratory and critical care medicine*. 2007; 176:957–69. [PubMed: 17761616]
57. King PT, Holmes PW. Use of antibiotics in bronchiectasis. *Reviews on recent clinical trials*. 2012; 7:24–30. [PubMed: 22023177]
58. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. *American journal of respiratory and critical care medicine*. 2011; 183:491–9. [PubMed: 20870753]
59. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. *The lancet Respiratory medicine*. 2014; 2:738–49. [PubMed: 25154045]
60. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic *Pseudomonas aeruginosa* infection. *American journal of respiratory and critical care medicine*. 2014; 189:975–82. [PubMed: 24625200]
61. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. *The Cochrane database of systematic reviews*. 2007:CD001392. [PubMed: 17443506]
62. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of *Pseudomonas* eradication therapy in patients with non-cystic fibrosis bronchiectasis. *Respiratory medicine*. 2012; 106:356–60. [PubMed: 22204744]
63. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. *Jama*. 2013; 309:1260–7. [PubMed: 23532242]
64. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. *Jama*. 2013; 309:1251–9. [PubMed: 23532241]
65. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2012; 380:660–7. [PubMed: 22901887]

66. Smit HJ, Schreurs AJ, Van den Bosch JM, Westermann CJ. Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia? *Chest*. 1996; 109:1541–4. [PubMed: 8769508]
67. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. *The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation*. 2012; 31:1073–86.
68. Campbell R. Managing upper respiratory tract complications of primary ciliary dyskinesia in children. *Current opinion in allergy and clinical immunology*. 2012; 12:32–8. [PubMed: 22157161]
69. Pruliere-Escabasse V, Coste A, Chauvin P, et al. Otologic features in children with primary ciliary dyskinesia. *Archives of otolaryngology–head & neck surgery*. 2010; 136:1121–6. [PubMed: 21079168]
70. Parsons DS, Greene BA. A treatment for primary ciliary dyskinesia: efficacy of functional endoscopic sinus surgery. *The Laryngoscope*. 1993; 103:1269–72. [PubMed: 8231581]
71. Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. *The European respiratory journal*. 1997; 10:2376–9. [PubMed: 9387968]




Figure 1. Diagrammatic representation of a normal ciliary cross section illustrating major ultrastructural components.




Figure 2. A diagnostic algorithm for Primary ciliary dyskinesia (PCD)

*But if clinical suspicion is still high for PCD, may go to other, more specific tests

**A nasal NO level less than 77 nl/minute has a sensitivity and specificity of 0.98 and >0.99 respectively

***Normal ciliary beat frequency and pattern does not exclude PCD

Nml: normal; PCD: Abnml: abnormal, NO: nitric oxide

Table 1

Clinical Signs and Symptoms of Primary ciliary dyskinesia

By system affected	By age of presentation
<ul style="list-style-type: none"> • <u>Middle Ear</u> <ul style="list-style-type: none"> ➤ Chronic otitis media with tube placement ➤ Conductive hearing loss • <u>Nose and para-nasal sinuses</u> <ul style="list-style-type: none"> ➤ Neonatal rhinitis ➤ Chronic rhino-sinusitis ➤ Chronic pan-sinusitis ➤ Nasal polyposis • <u>Lung</u> <ul style="list-style-type: none"> ➤ Neonatal respiratory distress ➤ Chronic cough ➤ Recurrent pneumonia ➤ Bronchiectasis • <u>Genitourinary Tract</u> <ul style="list-style-type: none"> ➤ Male/female fertility problem or history of in vitro fertilization • <u>Laterality defects</u> <ul style="list-style-type: none"> ➤ Situs inversus totalis ➤ Heterotaxy (+/- congenital cardiovascular abnormalities) • <u>Central nervous system</u> <ul style="list-style-type: none"> ➤ Hydrocephalus • <u>Eye</u> <ul style="list-style-type: none"> ➤ Retinitis pigmentosa 	<ul style="list-style-type: none"> • <u>Family history</u> <ul style="list-style-type: none"> ➤ Communities or ethnicities with consanguinity ➤ Close (usually first degree) relatives with clinical symptoms • <u>Antenatal</u> <ul style="list-style-type: none"> ➤ Heterotaxy on prenatal ultrasound • <u>Newborn period</u> <ul style="list-style-type: none"> ➤ Continuous rhinorrhoea ➤ Respiratory distress or neonatal pneumonia • <u>Childhood</u> <ul style="list-style-type: none"> ➤ Chronic productive cough ➤ Atypical asthma unresponsive to therapy ➤ Idiopathic bronchiectasis ➤ Chronic rhinosinusitis ➤ Recurrent otitis media with effusion • <u>Adolescence and adult life</u> <ul style="list-style-type: none"> ➤ Same as for childhood ➤ Subfertility and ectopic pregnancies in females ➤ Infertility in males with immotile sperm ➤ Sputum colonization with non-tuberculosis mycobacterium or smooth/mucoid pseudomonas

Table 2
Primary ciliary dyskinesia-associated genes in humans showing extensive locus heterogeneity

Human Gene	Chromosomal location	Axonemal Component	Ultra-structure defect	* Phenotype, gene OMIM#	PCD locus
<i>DNAH5</i>	5p15.2	ODA dynein HC	ODA defect	608644, 603335	CILD3
<i>DNAI1</i>	9p21-p13	ODA dynein IC	ODA defect	244400, 604366	CILD1
<i>DNAI2</i>	17q25	ODA dynein IC	ODA defect	612444, 605483	CILD9
<i>DNAL1</i>	14q24.3	ODA dynein LC	ODA defect	610062, 614017	CILD16
<i>TXNDC3 (NME8)</i>	7p14-p13	ODA dynein IC/LC	Partial ODA defect (66% cilia defective)	610852, 607421	CILD6
<i>CCDC114</i>	19q13.32	ODA DC	ODA defect	615067, 615038	CILD20
<i>CCDC151</i>	19q13.32	ODA DC	ODA defect	616037, 615956	CILD30
<i>ARMC4</i>	10p12.1-p11.23	ODA transport component	ODA defect	615451, 615408	CILD23
<i>DNAAF1 (LRRC50)</i>	16q24.1	Cytoplasmic DA preassembly factor	ODA + IDA defect	613193, 613190	CILD13
<i>DNAAF2 (KTU)</i>	14q21.3	Cytoplasmic DA preassembly factor	ODA + IDA defect	612518, 612517	CILD10
<i>DNAAF3 (C19ORF51)</i>	19q13.42	Cytoplasmic DA preassembly factor	ODA + IDA defect	606763, 614566	CILD2
<i>CCDC103</i>	17q21.31	Cytoplasmic DA attachment factor	ODA + IDA defect	614679, 614677	CILD17
<i>C21orf59</i>	21q22.1	Cytoplasmic DA assembly or adaptor for transport	ODA + IDA defect	615500, 615494	CILD26
<i>DYX1C1</i>	15q21.3	Cytoplasmic DA preassembly factor	ODA + IDA defect	615482, 608706,	CILD25
<i>LRRC6</i>	8q24	Cytoplasmic DA preassembly &/or transport	ODA + IDA defect	614935, 614930	CILD19
<i>HEATR2</i>	7p22.3	Cytoplasmic DA preassembly or transport	ODA + IDA defect	614874, 614864	CILD18
<i>SPAG1</i>	8q22	Cytoplasmic DA preassembly or transport	ODA + IDA defect	615505, 603395	CILD28
<i>ZMYND10</i>	3p21.31	Cytoplasmic DA assembly	ODA + IDA defect	615444, 607070	CILD22
<i>CCDC39</i>	3q26.33	N-DRC	IDA defect + microtubular disorganization	613807, 613798	CILD14
<i>CCDC40</i>	17q25.3	N-DRC	IDA defect + microtubular disorganization	613808, 613799	CILD15
<i>CCDC65 (DRC2)</i>	12q13.12	N-DRC	Mostly normal, CA defects in small proportion of cilia	615504, 611088	CILD27
<i>CCDC164 (DRC1)</i>	2p23.3	N-DRC	Nexin (N-DRC) link missing; axonemal disorganization in small proportion of cilia	615294, 615288	CILD21
<i>RSPH1</i>	21q22.3	RS component	Mostly normal, CA defects in small proportion of cilia	615481, 609314	CILD24

Human Gene	Chromosomal location	Axonemal Component	Ultra-structure defect	* Phenotype, gene OMIM#	PCD locus
<i>RSPH4A</i>	6q22.1	RS component	Mostly normal, CA defects in small proportion of cilia	612647, 612649	CILD11
<i>RSPH9</i>	6p21.1	RS component	Mostly normal, CA defects in small proportion of cilia	612650, 612648	CILD12
<i>HYDIN</i>	16q22.2	CA component	Normal, very occasionally CA defects	608647, 610812	CILD5
<i>DNAH11</i>	7p21	ODA dynein HC	Normal	611884, 603339	CILD7
<i>CCNO</i>	5q11.2	Required for cilia biogenesis	Ciliary a/oligoplasia	615872, 607752	CILD29
<i>MCIDAS</i>	5q11.2	Required for cilia biogenesis	Ciliary a/oligoplasia	NA, 614086	NA
<i>DNAH8</i> ****	6p21.1	ODA dynein HC	NA	603337, NA	NA
<i>RPGR</i> **	Xp21.1	outer segment of Rod & Con photoreceptors	Mixed	300455, 312610	NA
<i>OFD1</i> ***	Xq22	Centriole component, required for cilia biogenesis	NA	300209, 300170	NA

DA: Dynein arm; ODA: outer dynein arm; IC: intermediate chain; HC: heavy chain; LC: light chain; RS: radial spokes; IDA: inner dynein arm; CA: central apparatus; N-DRC: nexin-dynein regulatory complex; DC: docking complex; NA: not available

* Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org/>

** Co-segregation of X-linked PCD with X-linked Retinitis Pigmentosa

*** Co-segregation of X-linked PCD with X-linked Mental Retardation

**** Ciliary ultrastructure not available⁵⁰, however, *DNAH8* is paralogous to *DNAH5*.